Characteristics of aplastic anemia patients included in EPAG-IST group and historic IST group
EPAG-IST group . | Historic IST group (n = 102) . | P* . | ||||
---|---|---|---|---|---|---|
Cohort 1 (n = 30) . | Cohort 2 (n = 31) . | Cohort 3 + extension (n = 117) . | All patients (n = 178) . | |||
Age distribution (y), n (%) | ||||||
<18 | 5 (17) | 6 (19) | 33 (28) | 44 (25) | 23 (23) | .68 |
18-39 | 11 (37) | 13 (42) | 40 (34) | 64 (36) | 41 (40) | .49 |
40-60 | 8 (27) | 9 (29) | 22 (19) | 39 (22) | 22 (22) | .95 |
>60 | 6 (20) | 3 (10) | 22 (19) | 31 (17) | 16 (16) | .71 |
Disease severity, n (%) | ||||||
VSAA | 13 (43) | 10 (32) | 53 (45) | 76 (43) | 35 (34) | .16 |
SAA | 17 (57) | 21 (68) | 64 (55) | 102 (57) | 67 (66) | |
Treatment, n (%) | ||||||
3 mo EPAG | — | 31 (100) | — | 31 (18) | — | |
6 mo EPAG | 30 (100) | — | 117 (100) | 147 (82) | — | |
No CSA maintenance | 30 (100) | 14 (45) | — | 44 (25) | — | |
CSA maintenance | — | 17 (55) | 117 (100) | 134 (75) | 102 (100) | <.001 |
6 mo response, n (%) | ||||||
Overall response | 24 (80) | 27 (87) | 94 (80) | 145 (81) | 68 (67) | .008 |
Complete response | 10 (33) | 8 (26) | 51 (44) | 69 (39) | 17 (17) | <.001 |
Partial response | 14 (47) | 19 (61) | 43 (37) | 76 (43) | 51 (50) | .24 |
No response | 3 (10) | 2 (6) | 11 (9) | 16 (9) | 30 (29) | <.001 |
Off study | 3 (10) | 2 (6) | 12 (10) | 17 (10) | 4 (4) | .06 |
Baseline GPI; deficient neutrophils, n (%) | ||||||
<1% | 22 (73) | 19 (61) | 77 (66) | 118 (66) | 59 (58) | .17 |
≥1% | 8 (27) | 12 (39) | 40 (34) | 60 (34) | 43 (42) | |
Baseline telomere length, n (%) | ||||||
<10% | 8 (27) | 7 (23) | 13 (11) | 28 (16) | N/A | N/A |
≥10% | 22 (73) | 24 (77) | 100 (85) | 146 (82) | N/A | |
Median time to follow up,† mo (range) | 73.5 (2.8-99.2) | 62.9 (5.6-74.1) | 36.5 (3.2-65.6) | 48.7 (2.8-99.2) | 87.8 (2.9–190.8) | <.001 |
EPAG-IST group . | Historic IST group (n = 102) . | P* . | ||||
---|---|---|---|---|---|---|
Cohort 1 (n = 30) . | Cohort 2 (n = 31) . | Cohort 3 + extension (n = 117) . | All patients (n = 178) . | |||
Age distribution (y), n (%) | ||||||
<18 | 5 (17) | 6 (19) | 33 (28) | 44 (25) | 23 (23) | .68 |
18-39 | 11 (37) | 13 (42) | 40 (34) | 64 (36) | 41 (40) | .49 |
40-60 | 8 (27) | 9 (29) | 22 (19) | 39 (22) | 22 (22) | .95 |
>60 | 6 (20) | 3 (10) | 22 (19) | 31 (17) | 16 (16) | .71 |
Disease severity, n (%) | ||||||
VSAA | 13 (43) | 10 (32) | 53 (45) | 76 (43) | 35 (34) | .16 |
SAA | 17 (57) | 21 (68) | 64 (55) | 102 (57) | 67 (66) | |
Treatment, n (%) | ||||||
3 mo EPAG | — | 31 (100) | — | 31 (18) | — | |
6 mo EPAG | 30 (100) | — | 117 (100) | 147 (82) | — | |
No CSA maintenance | 30 (100) | 14 (45) | — | 44 (25) | — | |
CSA maintenance | — | 17 (55) | 117 (100) | 134 (75) | 102 (100) | <.001 |
6 mo response, n (%) | ||||||
Overall response | 24 (80) | 27 (87) | 94 (80) | 145 (81) | 68 (67) | .008 |
Complete response | 10 (33) | 8 (26) | 51 (44) | 69 (39) | 17 (17) | <.001 |
Partial response | 14 (47) | 19 (61) | 43 (37) | 76 (43) | 51 (50) | .24 |
No response | 3 (10) | 2 (6) | 11 (9) | 16 (9) | 30 (29) | <.001 |
Off study | 3 (10) | 2 (6) | 12 (10) | 17 (10) | 4 (4) | .06 |
Baseline GPI; deficient neutrophils, n (%) | ||||||
<1% | 22 (73) | 19 (61) | 77 (66) | 118 (66) | 59 (58) | .17 |
≥1% | 8 (27) | 12 (39) | 40 (34) | 60 (34) | 43 (42) | |
Baseline telomere length, n (%) | ||||||
<10% | 8 (27) | 7 (23) | 13 (11) | 28 (16) | N/A | N/A |
≥10% | 22 (73) | 24 (77) | 100 (85) | 146 (82) | N/A | |
Median time to follow up,† mo (range) | 73.5 (2.8-99.2) | 62.9 (5.6-74.1) | 36.5 (3.2-65.6) | 48.7 (2.8-99.2) | 87.8 (2.9–190.8) | <.001 |